JPRN-jRCT2080223131未知2 期
ST-605 phase 2 study - uncontrolled open-label study in patients with cytomegalovirus corneal endotheliitis
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients who diagnose as CMV endotheliitis based on the clinical manifestations of (1) or (2).
- •(1) Patients who show coin-shaped lesionsl or inear keratic precipitates (KPs).
- •(2) Patients who show other KPs combined with more than 2 of following signs; anterior uveitis, ocular hypertension and corneal endothelial cell loss.
- •2) Patients who are CMV DNA positive by examination of qualitative PCR of aqueous humor.
- •3) Patients who consent for collecting aqueous humor by anterior chamber tap.
排除标准
- •1) Patients who are HSV or VZV positive by examination of qualitative PCR of aqueous humor.
- •2) Patients who diagnose as CMV endotheliitis with other causes than CMV.
- •3) Patients who receive anti-CMV drugs such as ganciclovir, valganciclovir or foscarnet within 4 weeks of enrollment.
- •4) Patients who are allergic to ganciclovir.
- •5) Patients who diagnose CMV retinopathy.
研究者
相似试验
进行中（未招募）
不适用
First Line chemotherapy treatment with the chemotherapeutic regimenFOLFOX6 in combination with regorafenib of patients with bowel cancerEUCTR2010-020121-41-DEBayer HealthCare AG41
进行中（未招募）
1 期
This clinical study evaluates the tumor response rate in patients with cancer of the colon or rectum who are receiving regorafenib in combination with chemotherapy.Metastatic adenocarcinoma of the colon or rectum (metastatic CRC)MedDRA version: 16.1 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 100000004864EUCTR2010-020121-41-GBBayer Health Care AG, D-51368 Leverkusen54
进行中（未招募）
不适用
An uncontrolled, open-label, phase II study in subjects with metastatic adenocarcinoma of the colon or rectum who are receiving first line chemotherapy with mFOLFOX6 (oxaliplatin/ folinic acid/5-fluorouracil [5-FU]) in combination with regorafenib - NDMetastatic adenocarcinoma of the colon or rectum (metastatic CRC)MedDRA version: 9.1Level: PTClassification code 10052358EUCTR2010-020121-41-ITBayer HealthCare AG41
进行中（未招募）
不适用
First Line chemotherapy treatment with the chemotherapeutic regimen FOLFOX6 in combination with regorafenib of patients with bowel cancerMetastatic adenocarcinoma of the colon or rectum (metastatic CRC)EUCTR2010-020121-41-BEBayer HealthCare AG41
进行中（未招募）
不适用
Randomized, open-label phase II study evaluating the safety and efficacy of Cetuximab plus modified FOLFOX - 6 versus modified FOLFOX - 6 alone as 2nd line therapy after progression on the 1st line treatment with Cetuximab + FOLFIRI in patients with metastatic colorectal cancer KRAS wild-type – TAGUS Study - TAGUS StudyEUCTR2008-008282-36-PTGrupo de Investigação do Cancro Digestivo